Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
By N. Ibrahim, N. Desai, S. Legha, P. Soon-Shiong, R. Theriault, E. Rivera, B. Esmaeli, S. Ring, A. Bedikian, G. Hortobagyi and 1 more. Clinical Cancer Research, 2002
649 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/e1fd6d0ce358a6271b464839242b3bd2dc7fd10b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- O. Koo
- I. Rubinstein
- H. Onyuksel
- R. Sinha
- Shuming Nie
- Gloria J. Kim
- D. Shin
- Dong-Wan Kim
Citations in the corpus
- Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies (2004, background): “The MTD of Genexol-PM was determined to be 390 mg/m2 in the present study, and that of ABI-007 is 300 mg/m2 (20).”
- Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer (2009, unknown): “Moreover, pharmacokinetic parameters showed a linear trend.(69)”
- Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. (2006, background): “Anderson, the new formulation was safely administered as a short IV infusion without steroid or antihistamine premedication [29].”
- Albumin-bound paclitaxel: a next-generation taxane (2006, background): “1 Phase I The first Phase I study with nab-paclitaxel examined its toxicity profile, maximum tolerated dose (MTD) and pharmacokinetics [62].”
- Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery (2006, background): “No hypersensitivity reactions were observed during the infusion period (44).”
- Role of nanotechnology in targeted drug delivery and imaging: a concise review. (2005, methodology): “Albumin nanoparticles Marketed Validation of lack of immune reactivity maybe required Paclitaxel [14] In vitro DNA and antisense oligonucleotides [176,177] Nanogels Preclinical Some polymers used may not yet be”